|
This complaint was reopened in reference to (b)(4).Manufacturing site evaluation: manufacturing and quality control data: the paedigav® was manufactured by a qualified employee in may 2015.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The paedigav has a fixed pressure of 9cmh20 in the horizontal and 29cmh20 in the vertical position.The valve was inspected as article fv301t.All parameters have been inspected and signed during the manufacturing process.All parameters have been assessed as meeting specification.Device examination: the paedigav® valve was returned submersed in an unidentified liquid.Visual inspection: a visual inspection was performed which revealed no deformations or other abnormalities.Permeability test: a permeability test has shown that the valve was permeable with difficulty.Computer controlled test: to investigate over/under-drainage, the opening pressure was measured using a miethke computer controlled testing apparatus which simulates a cerobrospinal fluid flow.The results showed that the valve was operating within the accepted tolerance in the vertical, but not in the horizontal position.Braking force and brake function test: the brake functionality test has shown that the brake function was fully operational and the braking force was within expected tolerances.Result: first, a visual inspection of the progav® was performed.No significant deformations or damage to the valve were detected.Next, the permeability of the valve was tested.The valve was shown to be permeable with difficulty.As a final examination, a computer controlled test was performed.He results showed that the valve was operating within the accepted tolerance in the vertical, but not in the horizontal position.Finally, the valve was dismantled.A small amount of build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, the valve showed a slower flow of liquid.This was likely due to the deposits observed inside the valve.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus (hc)-therapy by shunt implants.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke (b)(4).No further regulatory actions are required.
|